Location [1]
Receptor tyrosine kinase/growth factor signaling
Protein [2]
Receptor-type tyrosine-protein kinase FLT3
Synonyms [1]
CD135, STK1, FLK-2, FLK2

FLT3 (fms-related tyrosine kinase 3) encodes for the receptor-type tyrosine-protein kinase FLT3. FLT3 activates pathways in hematopoietic cells (Gene 2013). FLT3 is frequently mutated in acute myeloid leukemia, other hematologic malignancies, and colorectal cancer (COSMIC).

FLT3 is altered in 2.43% of all cancers with colorectal adenocarcinoma, non-small cell lung carcinoma, leukemia, melanoma, and breast carcinoma having the greatest prevalence of alterations [3].

FLT3 GENIE Cases - Top Diseases

The most common alterations in FLT3 are FLT3 Mutation (2.68%), FLT3 Amplification (0.51%), FLT3 D593_F594insNS (0.14%), FLT3 Loss (0.11%), and FLT3 Codon 835 Missense (0.09%) [3].

FLT3 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of FLT3 in Diseases

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Acute Lymphoblastic Leukemia +

Chronic Myeloid Leukemia +

Hodgkin Lymphoma +

Multiple Myeloma +

Chronic Myelomonocytic Leukemia +

Non-Hodgkin Lymphoma +

Acute Biphenotypic Leukemia +

Burkitt Lymphoma +

Mantle Cell Lymphoma +

Acute Leukemia +

Follicular Lymphoma +

Marginal Zone Lymphoma +

Chronic Lymphocytic Leukemia +

Anaplastic Large Cell Lymphoma +

Myeloproliferative Neoplasm +

Lymphoma +

Prolymphocytic Leukemia +

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +

Juvenile Myelomonocytic Leukemia +

Lymphoplasmacytic Lymphoma +

Malignant Solid Tumor +

Myelodysplastic/Myeloproliferative Neoplasm +

Myelofibrosis +

Small Lymphocytic Lymphoma +

Refractory Anemia With Excess Blasts +

Diffuse Large B-Cell Lymphoma +

B-Cell Non-Hodgkin Lymphoma +

Adult T-Cell Leukemia/Lymphoma +

Double-Hit Lymphoma +

Lymphoblastic Lymphoma +

Mature T-Cell And NK-Cell Lymphoma/Leukemia +

Plasma Cell Leukemia +

Acute Promyelocytic Leukemia +

B-Cell Acute Lymphoblastic Leukemia +

Blastic Plasmacytoid Dendritic Cell Neoplasm +

T-Cell Lymphoblastic Leukemia/Lymphoma +

Hematopoietic And Lymphoid Malignancy +

Acute Leukemia Of Ambiguous Lineage +

Acute Undifferentiated Leukemia +

Burkitt Leukemia +

Mature T-Cell And NK-Cell Neoplasm +

Mixed Phenotype Acute Leukemia +

Myeloid Sarcoma +

Natural Killer Cell Lymphoblastic Leukemia/Lymphoma +

Peripheral T-Cell Lymphoma +

Primary Myelofibrosis +

Refractory Anemia With Excess Blasts-2 +

T-Cell Non-Hodgkin Lymphoma +

T-Cell Prolymphocytic Leukemia +

Waldenstrom Macroglobulinemia +

Melanoma +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Anaplastic Astrocytoma +

Glioblastoma +

Non-Small Cell Lung Carcinoma +

Bladder Carcinoma +

Head And Neck Carcinoma +

Sarcoma +

Breast Carcinoma +

Colorectal Carcinoma +

Pancreatic Carcinoma +

Neuroblastoma +

Acute Erythroid Leukemia +

Acute Megakaryoblastic Leukemia +

Acute Myeloid Leukemia With Myelodysplasia-Related Changes +

Adult Acute Lymphoblastic Leukemia +

Aggressive Non-Hodgkin Lymphoma +

Aggressive Systemic Mastocytosis +

Angioimmunoblastic T-Cell Lymphoma +

B-Cell Prolymphocytic Leukemia +

Cancer +

Desmoplastic Small Round Cell Tumor +

Ewing Sarcoma +

Hepatosplenic T-Cell Lymphoma +

Langerhans Cell Histiocytosis +

Mast Cell Leukemia +

Mature B-Cell Lymphoma/Leukemia +

Mediastinal Large B-Cell Lymphoma +

Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +

Myeloma +

Neurofibromatosis Type 1 +

Ovarian Carcinoma +

Plasma Cell Neoplasm +

Polycythemia Vera +

Refractory Anemia +

Rhabdomyosarcoma +

Secondary Acute Myeloid Leukemia +

Secondary Myelodysplastic Syndrome +

Small Lymphocytic Leukemia +

T-Cell And NK-Cell Neoplasm +

Therapy-Related Acute Myeloid Leukemia +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.